Danish Study Finds No Autism Link with Tylenol Use in Pregnancy

• Among 31,098 children exposed to Tylenol in the womb, 1.8% were later diagnosed with autism compared to 3% in the unexposed group, showing lower rates in exposed children
• The FDA initiated a label change process in September to warn about potential autism and ADHD risks, while RFK Jr. previously claimed Tylenol 'definitively causes autism' before moderating his stance
• Multiple national and international medical groups have opposed restricting Tylenol use during pregnancy, and the FDA declined to comment on the status of its planned label change

Summary: Danish Study Finds No Autism Link with Tylenol Use in Pregnancy

A comprehensive Danish nationwide study published Monday found no association between Tylenol (acetaminophen/paracetamol) use during pregnancy and autism in children, potentially easing long-standing concerns about the common pain reliever.

Key Findings

The study examined over 1.5 million children born between 1997 and 2022, including 31,098 exposed to Tylenol in utero. Results showed autism diagnoses in 1.8% of exposed children versus 3% of unexposed children—indicating lower rates among the exposed group. The absence of correlation held even after accounting for dosage and trimester of use.

Regulatory Context

This study contradicts earlier research and regulatory actions:

• A U.S. meta-analysis of 46 studies suggested a possible link between prenatal acetaminophen exposure and neurodevelopmental disorders, though it couldn't prove causation
• In September, the FDA initiated label change procedures to warn about potential autism and ADHD risks
• U.S. Health Secretary Robert F. Kennedy Jr. has stated Tylenol "definitively causes autism," though later recommended cautious use
• National and international medical groups have previously disputed claims of definitive links

Market Implications

The study provides reassurance for manufacturers and retailers of acetaminophen products. The FDA declined to comment on the status of its planned label change, creating continued regulatory uncertainty. The findings may influence:

• Consumer confidence in over-the-counter pain relievers
• Potential liability concerns for manufacturers
• Healthcare provider prescribing practices
• Ongoing regulatory decisions regarding product labeling

This research adds significant data to the ongoing debate about acetaminophen safety during pregnancy.